561 related articles for article (PubMed ID: 27816189)
1. Systemic therapy for HER2-positive early-stage breast cancer.
Mathew A; Romond EH
Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
[TBL] [Abstract][Full Text] [Related]
2. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
5. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
6. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Mery B; Toussaint P; Heudel PE; Dufresne A; Carbonnaux M; Vanacker H; Bachelot T; Trédan O
Bull Cancer; 2021 Dec; 108(11S):11S8-11S18. PubMed ID: 34969516
[TBL] [Abstract][Full Text] [Related]
9. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
10. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
11. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
12. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
13. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
14. The adjuvant treatment of HER2-positive breast cancer.
Jelovac D; Wolff AC
Curr Treat Options Oncol; 2012 Jun; 13(2):230-9. PubMed ID: 22410709
[TBL] [Abstract][Full Text] [Related]
15. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
16. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Awada A; Bozovic-Spasojevic I; Chow L
Cancer Treat Rev; 2012 Aug; 38(5):494-504. PubMed ID: 22305205
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab and trastuzumab: the rationale way to synergy.
Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
[TBL] [Abstract][Full Text] [Related]
18. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HER2-positive breast cancer: current status and future perspectives.
Arteaga CL; Sliwkowski MX; Osborne CK; Perez EA; Puglisi F; Gianni L
Nat Rev Clin Oncol; 2011 Nov; 9(1):16-32. PubMed ID: 22124364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]